Regulation of mitosis and taxane response by Daxx and Rassf1

Oncogene

Volumn 31, Issue 1, 2012, Pages 13-26

  Giovinazzi, S ^a   Lindsay, C R ^a   Morozov, V M ^a   Escobar Cabrera, E ^b   Summers, M K ^c,e   Han, H S ^d   McIntosh, L P ^b   Ishov, A M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c GENENTECH INC   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

APC; Daxx; mitosis; Rassf1A C; SAC; taxane chemotherapy

Indexed keywords

CYCLIN B; DAXX PROTEIN; PACLITAXEL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANAPHASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN B1; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MITOSIS; NUCLEAR PROTEINS; PACLITAXEL; TUMOR SUPPRESSOR PROTEINS;

EID: 84855351925     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.211     Document Type: Article

References (56)

1. Aapro MS. (2001). Neoadjuvant therapy in breast cancer: can we define its role? Oncologist 6(Suppl 3): 36-39. (Pubitemid 32423185)
2. Agathanggelou A, Cooper WN, Latif F. (2005). Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508. (Pubitemid 40616319)
3. Amaar YG, Baylink DJ, Mohan S. (2005). Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and apotential regulator of osteoblast cell proliferation. J Bone Miner Res 20: 1430-1439. (Pubitemid 41033527)
4. Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P et al. (1999). Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35: 1431-1439. (Pubitemid 29454643)
5. Brito DA, Rieder CL. (2006). Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194-1200. (Pubitemid 43867292)
6. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. (2003). Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116: 2987-2998. (Pubitemid 36926987)
7. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. (2006). BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5: 1001-1007.
8. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369. (Pubitemid 36957839)
9. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL et al. (2005). Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23: 1169-1177. (Pubitemid 46202273)
10. Crown J, O'Leary M, Ooi WS. (2004). Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl 2): 24-32. (Pubitemid 38747840)
11. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD et al. (2004). RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64: 4112-4116. (Pubitemid 38802412)
12. De Mulder PH. (1999). The chemotherapy of head and neck cancer. Acta Otorhinolaryngol Belg 53: 247-252.
13. Escobar-Cabrera E, Lau DK, Giovinazzi S, Ishov AM, McIntosh LP. (2010). Structural characterization of the DAXX N-terminal helical bundle domain and its complex with Rassf1C. Structure 18: 1642-1653.
14. Estrabaud E, Lassot I, Blot G, Le Rouzic E, Tanchou V, Quemeneur E et al. (2007). RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP. Cancer Res 67: 1054-1061.
15. Hari M, Wang Y, Veeraraghavan S, Cabral F. (2003a). Mutations in alpha-and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2: 597-605.
16. Hari M, Yang H, Zeng C, Canizales M, Cabral F. (2003b). Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 56: 45-56. (Pubitemid 37059485)
17. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. (2003). Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983. (Pubitemid 46594124)
18. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221-234.
19. Ishov AM, Vladimirova OV, Maul GG. (2004). Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 117: 3807-3820. (Pubitemid 39207319)
20. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y et al. (2005). Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431. (Pubitemid 46224217)
21. Kitagawa D, Kajiho H, Negishi T, Ura S, Watanabe T, Wada T et al. (2006). Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation. EMBO J 25: 3286-3297. (Pubitemid 44141787)
22. Kubota T, Matsuzaki SW, Hoshiya Y, Watanabe M, Kitajima M, Asanuma F et al. (1997). Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64: 115-121. (Pubitemid 27106713)
23. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. (2004). Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 3: 661-669. (Pubitemid 39193746)
24. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T et al. (2003). Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947. (Pubitemid 36758615)
25. Lindsay CR, Giovinazzi S, Ishov AM. (2009). Daxx is a predominately nuclear protein that does not translocate to the cytoplasm in response to cell stress. Cell Cycle 8: 1544-1551.
26. Lindsay CR, Morozov VM, Ishov AM. (2008). PML NBs (ND10) and Daxx: from nuclear structure to protein function. Front Biosci 13: 7132-7142.
27. Lindsay CR, Scholz A, Morozov VM, Ishov AM. (2007). Daxx shortens mitotic arrest caused by paclitaxel. Cell Cycle 6: 1200-1204. (Pubitemid 47327986)
28. Liu L, Baier K, Dammann R, Pfeifer GP. (2007). The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex. Cell Cycle 6: 1663-1665. (Pubitemid 47327954)
29. Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP. (2003). Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22: 8125-8136. (Pubitemid 37487303)
30. Mantel C, Guo Y, Lee MR, Han MK, Rhorabough S, Kim KS et al. (2008). Cells enter a unique intermediate 4N stage, not 4N-G1, after aborted mitosis. Cell Cycle 7: 484-492. (Pubitemid 351366477)
31. Mauriac L, Debled M, MacGrogan G. (2005). When will more useful predictive factors be ready for use? Breast 14: 617-623. (Pubitemid 41683588)
32. Meraldi P, Draviam VM, Sorger PK. (2004). Timing and checkpoints in the regulation of mitotic progression. Dev Cell 7: 45-60. (Pubitemid 39172687)
33. Michaelson JS. (2000). The Daxx enigma. Apoptosis 5: 217-220.
34. Michaelson JS, Bader D, Kuo F, Kozak C, Leder P. (1999a). Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev 13: 1918-1923. (Pubitemid 29407359)
35. Michaelson JS, Bader D, Kuo F, Kozak C, Leder P. (1999b). Loss of daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development [In Process Citation]. Genes Dev 13: 1918-1923. (Pubitemid 29407359)
36. Miyoshi Y, Kim SJ, Akazawa K, Kamigaki S, Ueda S, Yanagisawa Tet al. (2004). Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res 10: 8163-8169. (Pubitemid 40053374)
37. Morozov VM, Massoll NA, Vladimirova OV, Maul GG, Ishov AM. (2008). Regulation of c-met expression by transcription repressor Daxx. Oncogene 27: 2177-2186. (Pubitemid 351483387)
38. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K. (2007). BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 178: 283-296. (Pubitemid 47076464)
39. Nilsson J, Yekezare M, Minshull J, Pines J. (2008). The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol 10: 1411-1420.
40. O'Shaughnessy J. (2005). Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3): 20-29. (Pubitemid 43152727)
41. Ravdin P, Erban J, Overmoyer B. (2003). Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer (abstract). Eur J Cancer (Suppl 1): 32.
42. Rong R, Jiang LY, Sheikh MS, Huang Y. (2007). Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 26: 7700-7708. (Pubitemid 350224218)
43. Rong R, Jin W, Zhang J, Sheikh MS, Huang Y. (2004). Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 23: 8216-8230. (Pubitemid 39531833)
44. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. (2005). The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306-1313. (Pubitemid 41752911)
45. Saffert RT, Kalejta RF. (2008). Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices, or both? Fut Virol 3: 265-277. (Pubitemid 351715806)
46. Salomoni P, Khelifi AF. (2006). Daxx: death or survival protein? Trends Cell Biol 16: 97-104. (Pubitemid 43247405)
47. Scolnick DM, Halazonetis TD. (2000). Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435. (Pubitemid 30625565)
48. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK et al. (2004). The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137. (Pubitemid 38425712)
49. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS. (2008). The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J 27: 1863-1874.
50. Sudo T, Nitta M, Saya H, Ueno NT. (2004). Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508. (Pubitemid 38523906)
51. Summers MK, Pan B, Mukhyala K, Jackson PK. (2008). The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell 31: 544-556.
52. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E et al. (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498-512. (Pubitemid 46856907)
53. Wang Y, Cabral F. (2005). Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 1744: 245-255. (Pubitemid 40798929)
54. Wassmann K, Benezra R. (2001). Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 11: 83-90. (Pubitemid 32119283)
55. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA. (2009). The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8: 876-888.
56. Xia G, Luo X, Habu T, Rizo J, Matsumoto T, Yu H. (2004). Conformation-specific binding of p31(comet) antagonizes the function of Mad2 in the spindle checkpoint. EMBO J 23:3133-3143. (Pubitemid 39093607)